Keros Therapeutics Earns Outperform Rating from Analysts at William Blair
KROS Stock | USD 14.57 0.41 2.90% |
Slightly above 62% of all Keros Therapeutics' private investors are looking to take a long position. The analysis of the overall investor sentiment regarding Keros Therapeutics suggests that some traders are interested. Keros Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Keros Therapeutics' earnings reports, geopolitical events, and overall market trends.
William Blair initiated coverage on shares of Keros Therapeutics in a note issued to investors on Wednesday, Briefing.com reports. The brokerage set an outperform rating on the stock. Several other equities analysts have also recently issued reports on KROS. Wells Fargo Company began coverage on shares of Keros Therapeutics
Read at thelincolnianonline.com
![]() |
Keros Therapeutics Current Investor Sentiment
Comfort Level 62
Interested
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Keros Therapeutics' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Keros Therapeutics.
News SentimentBullish | Hype SentimentBullish | Insider SentimentWaiting |
Keros Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Keros Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Keros Therapeutics Historical Investor Sentiment
Investor biases related to Keros Therapeutics' public news can be used to forecast risks associated with an investment in Keros. The trend in average sentiment can be used to explain how an investor holding Keros can time the market purely based on public headlines and social activities around Keros Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Keros Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Keros Therapeutics and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Keros Therapeutics news discussions. The higher the estimate score, the more favorable the investor's outlook on Keros Therapeutics.
Keros Therapeutics Fundamental Analysis
We analyze Keros Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Keros Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Keros Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Net Income
Net Income Comparative Analysis
Keros Therapeutics is currently under evaluation in net income category among its peers. Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Keros Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Keros Therapeutics stock to make a market-neutral strategy. Peer analysis of Keros Therapeutics could also be used in its relative valuation, which is a method of valuing Keros Therapeutics by comparing valuation metrics with similar companies.
Peers
Keros Therapeutics Related Equities
EWTX | Edgewise Therapeutics | 1.36 | ||||
ERAS | Erasca | 0.83 | ||||
MGTX | MeiraGTx Holdings | 0.79 | ||||
IDYA | Ideaya Biosciences | 0.75 | ||||
HRMY | Harmony Biosciences | 0.12 | ||||
JANX | Janux Therapeutics | 0.04 | ||||
FENC | Fennec Pharmaceuticals | 1.25 | ||||
ANAB | AnaptysBio | 1.45 | ||||
IPSC | Century Therapeutics | 1.75 | ||||
KZR | Kezar Life | 1.75 | ||||
GLUE | Monte Rosa | 1.98 | ||||
MLYS | Mineralys Therapeutics, | 2.21 | ||||
SRZN | Surrozen | 2.21 | ||||
BOLT | Bolt Biotherapeutics | 3.03 | ||||
LRMR | Larimar Therapeutics | 3.11 | ||||
REPL | Replimune | 4.68 | ||||
SNDX | Syndax Pharmaceuticals | 8.88 |
Additional Tools for Keros Stock Analysis
When running Keros Therapeutics' price analysis, check to measure Keros Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Keros Therapeutics is operating at the current time. Most of Keros Therapeutics' value examination focuses on studying past and present price action to predict the probability of Keros Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Keros Therapeutics' price. Additionally, you may evaluate how the addition of Keros Therapeutics to your portfolios can decrease your overall portfolio volatility.